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by stratification according to the institution and the clinical measurability of disease. The median duration of follow-up was 37 months (range: 5 -56).
Analysis of effectiveness
The analysis was based on intention to treat. Primary outcomes were response rate, adverse reaction incidence (using the toxicity severity criteria of the Gynecologic Oncology Group, based on all those patients with at least one course of treatment; of those randomised, only one patient was excluded from the analysis) and survival duration. Those having a complete response and those without a measurable disease, underwent a reassessment laparotomy to determine the pathological response. Progression-free survival was also analysed. The groups were comparable in terms of age, Gynaecologic Oncology Group performance status, cell type, tumour grade, measurability of disease, stage and presence of ascites (>100 ml). Groups were also comparable in terms of the total planned (450 mg per square metre)and delivered dose of cisplatin.
Effectiveness results
For those 216 women with measurable disease, 73% in TP and 60% CP responded to therapy, (p=0.01). The laparoscopic reassessment showed no difference (20% and 26%, p>0.05) between treatment arms in terms of complete response. The median survival was 38 and 24 months, respectively for the TP and CP groups (p<0.001). Progressionfree survival was 18 months for the TP and 13 months for the CP group, (p<0.001). The frequency of grade 4 neutropenia (the most severe) was 78% and 61% in the TP and CP, respectively, (p<0.05 for test of overall difference in severity between groups). Alopecia, fever and allergic reactions were also observed more frequently in the TP group (p<0.05 for test of overall difference in severity between groups). The mean survival duration was estimated to be 2.03 years in the CP group and 3.13 years in the TP group.
Modelling
An economic model was used to determine whether the alternative paclitaxel-cisplatin (TP) therapy was costeffectivein comparison to standard cyclophosphamide-cisplatin (CP) therapy. The model was based on the recommendations of a panel of practising clinical oncologists who compared the clinical trial resource use with resource use patterns of a 'real world' situation. Thus, they characterised adverse reaction treatment regimens and resource use consumption in general. The costing exercise assumed an administration of six full cycles of therapy. A Monte Carlo simulation was used to analyse the robustness of the estimates to variation in the data.
Measure of benefits used in the economic analysis
The measure of benefits was life years gained. The corresponding estimates were derived from the actual data (means) fromthe effectiveness study. No account was taken of the effects on benefits of adverse reactions to treatment.
Direct costs
Total drug acquisition, facility, adverse event management and follow-up therapy costs for CP and TP were included in the analysis. The costing was based on a 'real world' scenario of resource use as determined from the recommendations of an expert panel of five practising clinical oncologists who compared clinical trial data on resource use corresponding to the effectiveness study with general practice patterns of resource use. An activity-based costing approach was used in valuing costs using the Resource Based Relative Value Schedule (RBRVS) and drug acquisition costs derived from the Oncology Therapeutics Network (OTN) programme. Quantities of resource use associated with drug therapy (chemotherapy drug and concomitant medication) and adverse reaction management were analysed separately from costs. Costs were discounted. The quantity/cost boundary adopted was that of the hospital. The date of the price data was 1996.
